Literature DB >> 22993231

Intestine-specific expression of Apobec-1 rescues apolipoprotein B RNA editing and alters chylomicron production in Apobec1 -/- mice.

Valerie Blanc1, Yan Xie, Jianyang Luo, Susan Kennedy, Nicholas O Davidson.   

Abstract

Intestinal apolipoprotein B (apoB) mRNA undergoes C-to-U editing, mediated by the catalytic deaminase apobec-1, which results in translation of apoB48. Apobec1(-/-) mice produce only apoB100 and secrete larger chylomicron particles than those observed in wild-type (WT) mice. Here we show that transgenic rescue of intestinal apobec-1 expression (Apobec1(Int/O)) restores C-to-U RNA editing of apoB mRNA in vivo, including the canonical site at position 6666 and also at approximately 20 other newly identified downstream sites present in WT mice. The small intestine of Apobec1(Int/O) mice produces only apoB48, and the liver produces only apoB100. Serum chylomicron particles were smaller in Apobec1(Int/O) mice compared with those from Apobec1(-/-) mice, and the predominant fraction of serum apoB48 in Apobec1(Int/O) mice migrated in lipoproteins smaller than chylomicrons, even when these mice were fed a high-fat diet. Because apoB48 arises exclusively from the intestine in Apobec1(Int/O) mice and intestinal apoB48 synthesis and secretion rates were comparable to WT mice, we were able to infer the major sites of origin of serum apoB48 in WT mice. Our findings imply that less than 25% of serum apoB48 in WT mice arises from the intestine, with the majority originating from the liver.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22993231      PMCID: PMC3494256          DOI: 10.1194/jlr.M030494

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  36 in total

1.  Disproportionate relationship between APOBEC-1 expression and apolipoprotein B mRNA editing activity.

Authors:  J F Siddiqui; D Van Mater; M P Sowden; H C Smith
Journal:  Exp Cell Res       Date:  1999-10-10       Impact factor: 3.905

2.  Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif.

Authors:  S Yamanaka; K S Poksay; D M Driscoll; T L Innerarity
Journal:  J Biol Chem       Date:  1996-05-10       Impact factor: 5.157

3.  Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins.

Authors:  J Greeve; I Altkemper; J H Dieterich; H Greten; E Windler
Journal:  J Lipid Res       Date:  1993-08       Impact factor: 5.922

4.  Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48.

Authors:  K Hirano; S G Young; R V Farese; J Ng; E Sande; C Warburton; L M Powell-Braxton; N O Davidson
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

5.  Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation?

Authors:  Chun-Min Lo; Brian K Nordskog; Andromeda M Nauli; Shuqin Zheng; Sarah B Vonlehmden; Qing Yang; Dana Lee; Larry L Swift; Nicholas O Davidson; Patrick Tso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-11-15       Impact factor: 4.052

6.  An additional editing site is present in apolipoprotein B mRNA.

Authors:  N Navaratnam; D Patel; R R Shah; J C Greeve; L M Powell; T J Knott; J Scott
Journal:  Nucleic Acids Res       Date:  1991-04-25       Impact factor: 16.971

7.  Three distinct RNA sequence elements are required for efficient apolipoprotein B (apoB) RNA editing in vitro.

Authors:  J W Backus; H C Smith
Journal:  Nucleic Acids Res       Date:  1992-11-25       Impact factor: 16.971

8.  Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals.

Authors:  S Yamanaka; M E Balestra; L D Ferrell; J Fan; K S Arnold; S Taylor; J M Taylor; T L Innerarity
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

9.  Molecular cloning of an apolipoprotein B messenger RNA editing protein.

Authors:  B Teng; C F Burant; N O Davidson
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

10.  Multiple functions of microsomal triglyceride transfer protein.

Authors:  M Mahmood Hussain; Paul Rava; Meghan Walsh; Muhammad Rana; Jahangir Iqbal
Journal:  Nutr Metab (Lond)       Date:  2012-02-21       Impact factor: 4.169

View more
  10 in total

1.  Epithelial Indoleamine 2,3-Dioxygenase 1 Modulates Aryl Hydrocarbon Receptor and Notch Signaling to Increase Differentiation of Secretory Cells and Alter Mucus-Associated Microbiota.

Authors:  David M Alvarado; Baosheng Chen; Micah Iticovici; Ameet I Thaker; Nattalie Dai; Kelli L VanDussen; Nurmohammad Shaikh; Chai K Lim; Gilles J Guillemin; Phillip I Tarr; Matthew A Ciorba
Journal:  Gastroenterology       Date:  2019-07-17       Impact factor: 22.682

Review 2.  The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease.

Authors:  Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-05-26       Impact factor: 10.514

3.  Incorporating alternative splicing and mRNA editing into the genetic analysis of complex traits.

Authors:  Musa A Hassan; Jeroen P J Saeij
Journal:  Bioessays       Date:  2014-08-29       Impact factor: 4.345

4.  Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo.

Authors:  Bradley S Barrett; Kejun Guo; Michael S Harper; Sam X Li; Karl J Heilman; Nicholas O Davidson; Mario L Santiago
Journal:  Virology       Date:  2014-10-07       Impact factor: 3.616

5.  Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids Into Triglyceride Biosynthesis.

Authors:  Michele Alves-Bezerra; Yingxia Li; Mariana Acuña; Anna A Ivanova; Kathleen E Corey; Eric A Ortlund; David E Cohen
Journal:  Hepatology       Date:  2019-03-22       Impact factor: 17.425

6.  High-resolution genetic mapping in the diversity outbred mouse population identifies Apobec1 as a candidate gene for atherosclerosis.

Authors:  Tangi L Smallwood; Daniel M Gatti; Pamela Quizon; George M Weinstock; Kuo-Chen Jung; Liyang Zhao; Kunjie Hua; Daniel Pomp; Brian J Bennett
Journal:  G3 (Bethesda)       Date:  2014-10-23       Impact factor: 3.154

7.  PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction.

Authors:  Hua Sun; Ronald M Krauss; Jeffrey T Chang; Ba-Bie Teng
Journal:  J Lipid Res       Date:  2017-11-27       Impact factor: 5.922

8.  Epitranscriptomic profiling across cell types reveals associations between APOBEC1-mediated RNA editing, gene expression outcomes, and cellular function.

Authors:  Violeta Rayon-Estrada; Dewi Harjanto; Claire E Hamilton; Yamina A Berchiche; Emily Conn Gantman; Thomas P Sakmar; Karen Bulloch; Khatuna Gagnidze; Sheila Harroch; Bruce S McEwen; F Nina Papavasiliou
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-22       Impact factor: 11.205

9.  Genome-wide identification and functional analysis of Apobec-1-mediated C-to-U RNA editing in mouse small intestine and liver.

Authors:  Valerie Blanc; Eddie Park; Sabine Schaefer; Melanie Miller; Yiing Lin; Susan Kennedy; Anja M Billing; Hisham Ben Hamidane; Johannes Graumann; Ali Mortazavi; Joseph H Nadeau; Nicholas O Davidson
Journal:  Genome Biol       Date:  2014-06-19       Impact factor: 13.583

10.  Induction of body weight loss through RNAi-knockdown of APOBEC1 gene expression in transgenic rabbits.

Authors:  Geneviève Jolivet; Sandrine Braud; Bruno DaSilva; Bruno Passet; Erwana Harscoët; Céline Viglietta; Thomas Gautier; Laurent Lagrost; Nathalie Daniel-Carlier; Louis-Marie Houdebine; Itzik Harosh
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.